CLINICAL TRIALS PROFILE FOR SOLABEGRON

Clinical Trials for Solabegron

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00343486 ↗	Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms	Completed	GlaxoSmithKline	Phase 2	This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder.
NCT00394186 ↗	A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)	Completed	GlaxoSmithKline	Phase 2	This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients.
NCT00401479 ↗	A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers	Completed	GlaxoSmithKline	Phase 1	This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time.
NCT00427596 ↗	A Two-Part Study to Determine: Best Medication Formulation and Food Effect	Completed	GlaxoSmithKline	Phase 1	This is a two-part study. Part 1 is designed to find the best modified release formulation of GW423753; Part 2 is designed to use the selected formulation(s) from Part 1 to find out if food affects the way the medication is processed by the body.
NCT00501267 ↗	A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder	Completed	GlaxoSmithKline	Phase 1	The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together
NCT02938507 ↗	Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects	Completed	Velicept Therapeutics, Inc.	Phase 1	The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.

Clinical Trial Conditions for Solabegron

Condition Name

Condition Name for
Intervention	Trials
Overactive Bladder	5
Irritable Bowel Syndrome (IBS)	2
Healthy Subjects, Overactive Bladder	1

Condition MeSH

Condition MeSH for
Intervention	Trials
Urinary Bladder, Overactive	6
Irritable Bowel Syndrome	2
Syndrome	1

Clinical Trial Locations for Solabegron

Trials by Country

Trials by Country for
Location	Trials
United States	59
Germany	8
Australia	7
Argentina	3
France	2

Trials by US State

Trials by US State for
Location	Trials
Arizona	2
Nebraska	2
California	2
Alabama	2
Connecticut	2

Clinical Trial Progress for Solabegron

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase	Trials
Phase 2	4
Phase 1	4

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase	Trials
Completed	8

Clinical Trial Sponsors for Solabegron

Sponsor Name

Sponsor Name for
Sponsor	Trials
GlaxoSmithKline	5
Velicept Therapeutics, Inc.	3

Sponsor Type

Sponsor Type for
Sponsor	Trials
Industry	8